A detailed history of Sphera Funds Management Ltd. transactions in 89bio, Inc. stock. As of the latest transaction made, Sphera Funds Management Ltd. holds 536,547 shares of ETNB stock, worth $3.69 Million. This represents 0.73% of its overall portfolio holdings.

Number of Shares
536,547
Previous 526,547 1.9%
Holding current value
$3.69 Million
Previous $4.22 Million 5.86%
% of portfolio
0.73%
Previous 0.62%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.36 - $9.66 $73,600 - $96,600
10,000 Added 1.9%
536,547 $3.97 Million
Q2 2024

Aug 14, 2024

BUY
$7.31 - $10.9 $77,961 - $116,248
10,665 Added 2.07%
526,547 $4.22 Million
Q1 2024

May 15, 2024

BUY
$8.13 - $13.77 $871,601 - $1.48 Million
107,208 Added 26.23%
515,882 $6 Million
Q4 2023

Feb 14, 2024

BUY
$6.66 - $16.03 $595,224 - $1.43 Million
89,373 Added 27.99%
408,674 $4.56 Million
Q3 2023

Nov 14, 2023

BUY
$15.06 - $19.41 $2.78 Million - $3.58 Million
184,301 Added 136.52%
319,301 $4.93 Million
Q2 2023

Aug 14, 2023

BUY
$14.15 - $22.03 $1.91 Million - $2.97 Million
135,000 New
135,000 $2.56 Million
Q4 2022

Feb 14, 2023

SELL
$5.52 - $12.73 $2.64 Million - $6.09 Million
-478,184 Reduced 72.59%
180,600 $2.3 Million
Q3 2022

Nov 14, 2022

BUY
$3.02 - $7.0 $630,527 - $1.46 Million
208,784 Added 46.4%
658,784 $3.81 Million
Q2 2022

Aug 15, 2022

BUY
$2.09 - $4.02 $940,499 - $1.81 Million
450,000 New
450,000 $1.45 Million
Q1 2021

May 17, 2021

SELL
$20.22 - $26.73 $1.41 Million - $1.87 Million
-69,939 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$23.16 - $28.08 $254,760 - $308,880
11,000 Added 18.66%
69,939 $1.7 Million
Q3 2020

Nov 12, 2020

BUY
$24.34 - $38.82 $1.43 Million - $2.29 Million
58,939 New
58,939 $1.51 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $320M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Sphera Funds Management Ltd. Portfolio

Follow Sphera Funds Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sphera Funds Management Ltd. with notifications on news.